BioWorld

March 24, 2009

Morphotek Gets SPA to Start Phase III Ovarian Cancer Trial

After yielding promising interim Phase II data, Morphotek Inc.'s farletuzumab is set to enter a pivotal, Phase III trial in ovarian cancer under a special protocol assessment. (BioWorld Today) Read More

Appeals Court Sides with Feds on GSK Patent Case

Merck Serono Launches Venture Fund with $54M Commitment

MDRNA Soars on siRNA Tech Deal with Novartis

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...